Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · ca8600d9-46e6-402d-89f9-bc6a156bf751

BOSULIF

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2026-03-10
Captured
2026-09-09T23:37:58.719708+00:00
Current indication reconciliation
Not reconciled

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )
Full extracted label fields
application numbers
  1. NDA203341
  2. NDA217729
boxed warning exact
    brand names
    1. BOSULIF
    current indication status
    not_reconciled
    dailymed set url
    https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3
    generic names
    1. BOSUTINIB
    id
    ca8600d9-46e6-402d-89f9-bc6a156bf751
    indications and usage exact
    1. 1 INDICATIONS AND USAGE BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )
    indications and usage tables exact
      is original packager
      1. true
      manufacturer names
      1. Pfizer Laboratories Div Pfizer Inc
      matched search terms
      1. leukemia
      package ndcs
      1. 0069-0135-01
      2. 0069-0136-01
      3. 0069-0193-01
      4. 0069-0504-30
      5. 0069-1014-15
      product ndcs
      1. 0069-0135
      2. 0069-0136
      3. 0069-0193
      4. 0069-0504
      5. 0069-1014
      product types
      1. HUMAN PRESCRIPTION DRUG
      recent major changes exact
        record type
        complete_spl_indications_section_candidate
        routes
        1. ORAL
        rxcuis
        1. 1307624
        2. 1307630
        3. 1307633
        4. 1307635
        5. 1987732
        6. 1987734
        7. 2669663
        8. 2669665
        9. 2672326
        10. 2672328
        source batch
        file
        /private/tmp/cancer-full-research/indications/raw/labels-00600.json
        meta
        disclaimer
        Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
        last updated
        2026-09-09
        results
        limit
        100
        skip
        600
        total
        830
        sha256
        a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
        url
        https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=600&sort=id%3Aasc
        source url
        https://api.fda.gov/drug/label.json?search=id%3A%22ca8600d9-46e6-402d-89f9-bc6a156bf751%22
        spl effective date
        2026-03-10
        spl effective time
        20260310
        spl set id
        adc84ad5-a04d-4fee-9ba8-91f7abd928e3
        spl version
        32
        substance names
        1. BOSUTINIB MONOHYDRATE
        uniis
        1. 844ZJE6I55
        verification flags
        1. oncology_keyword_candidate_not_clinically_classified
        2. spl_text_not_verified_identical_to_latest_approved_label
        3. individual_indications_not_split_or_reconciled
        Drugs@FDA application source records
        1. application number
          NDA203341
          payload
          all indexed label documents
          1. Appl No
            203341
            Application Docs Date
            2012-09-04 00:00:00
            Application Docs ID
            19458
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            1
            Submission Type
            ORIG
          2. Appl No
            203341
            Application Docs Date
            2015-10-06 00:00:00
            Application Docs ID
            19459
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            3
            Submission Type
            SUPPL
          3. Appl No
            203341
            Application Docs Date
            2016-04-05 00:00:00
            Application Docs ID
            19460
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            5
            Submission Type
            SUPPL
          4. Appl No
            203341
            Application Docs Date
            2013-09-30 00:00:00
            Application Docs ID
            40288
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            1
            Submission Type
            SUPPL
          5. Appl No
            203341
            Application Docs Date
            2015-01-05 00:00:00
            Application Docs ID
            40289
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            2
            Submission Type
            SUPPL
          6. Appl No
            203341
            Application Docs Date
            2016-11-17 00:00:00
            Application Docs ID
            45909
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            6
            Submission Type
            SUPPL
          7. Appl No
            203341
            Application Docs Date
            2017-04-18 00:00:00
            Application Docs ID
            48049
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            8
            Submission Type
            SUPPL
          8. Appl No
            203341
            Application Docs Date
            2017-04-18 00:00:00
            Application Docs ID
            48050
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            7
            Submission Type
            SUPPL
          9. Appl No
            203341
            Application Docs Date
            2017-12-19 00:00:00
            Application Docs ID
            50777
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            9
            Submission Type
            SUPPL
          10. Appl No
            203341
            Application Docs Date
            2018-10-19 00:00:00
            Application Docs ID
            56045
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            15
            Submission Type
            SUPPL
          11. Appl No
            203341
            Application Docs Date
            2019-08-15 00:00:00
            Application Docs ID
            59724
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            16
            Submission Type
            SUPPL
          12. Appl No
            203341
            Application Docs Date
            2019-10-10 00:00:00
            Application Docs ID
            60530
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            17
            Submission Type
            SUPPL
          all submission records
          1. Appl No
            203341
            Review Priority
            STANDARD
            Submission Class Code ID
            7
            Submission No
            1
            Submission Status
            AP
            Submission Status Date
            2012-09-04 00:00:00
            Submission Type
            ORIG
            Submissions Public Notes
          2. Appl No
            203341
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            1
            Submission Status
            AP
            Submission Status Date
            2013-09-30 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          3. Appl No
            203341
            Review Priority
            Submission Class Code ID
            3
            Submission No
            2
            Submission Status
            AP
            Submission Status Date
            2014-11-25 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          4. Appl No
            203341
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            3
            Submission Status
            AP
            Submission Status Date
            2015-09-22 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          5. Appl No
            203341
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            4
            Submission Status
            AP
            Submission Status Date
            2015-10-08 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          6. Appl No
            203341
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            5
            Submission Status
            AP
            Submission Status Date
            2016-04-04 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          7. Appl No
            203341
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            6
            Submission Status
            AP
            Submission Status Date
            2016-11-17 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          8. Appl No
            203341
            Review Priority
            STANDARD
            Submission Class Code ID
            2
            Submission No
            7
            Submission Status
            AP
            Submission Status Date
            2017-04-13 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          9. Appl No
            203341
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            8
            Submission Status
            AP
            Submission Status Date
            2017-04-13 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          10. Appl No
            203341
            Review Priority
            PRIORITY
            Submission Class Code ID
            2
            Submission No
            9
            Submission Status
            AP
            Submission Status Date
            2017-12-19 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          11. Appl No
            203341
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            13
            Submission Status
            AP
            Submission Status Date
            2018-05-01 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          12. Appl No
            203341
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            15
            Submission Status
            AP
            Submission Status Date
            2018-10-18 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          application number
          NDA203341
          approval interpretation
          Application linkage and approved submission are not indication-level current approval verification
          current indication status
          not_reconciled
          has approved submission record
          true
          latest approved submission date
          2026-03-02
          latest label selection rule
          max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
          latest posted label documents
          1. Appl No
            203341
            Application Docs Date
            2026-03-06 00:00:00
            Application Docs ID
            85286
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            27
            Submission Type
            SUPPL
          official application record
          Appl No
          203341
          Appl Public Notes
          Appl Type
          NDA
          Sponsor Name
          PF PRISM CV
          openfda application present
          true
          products
          1. Active Ingredient
            BOSUTINIB MONOHYDRATE
            Appl No
            203341
            Drug Name
            BOSULIF
            Form
            TABLET;ORAL
            Product No
            001
            Reference Drug
            1
            Reference Standard
            1
            Strength
            EQ 100MG BASE
            marketing status
            1. Prescription
          2. Active Ingredient
            BOSUTINIB MONOHYDRATE
            Appl No
            203341
            Drug Name
            BOSULIF
            Form
            TABLET;ORAL
            Product No
            002
            Reference Drug
            1
            Reference Standard
            0
            Strength
            EQ 500MG BASE
            marketing status
            1. Prescription
          3. Active Ingredient
            BOSUTINIB MONOHYDRATE
            Appl No
            203341
            Drug Name
            BOSULIF
            Form
            TABLET;ORAL
            Product No
            003
            Reference Drug
            1
            Reference Standard
            0
            Strength
            EQ 400MG BASE
            marketing status
            1. Prescription
        2. application number
          NDA217729
          payload
          all indexed label documents
          1. Appl No
            217729
            Application Docs Date
            2023-09-27 00:00:00
            Application Docs ID
            75571
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            1
            Submission Type
            ORIG
          2. Appl No
            217729
            Application Docs Date
            2024-12-05 00:00:00
            Application Docs ID
            80523
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            1
            Submission Type
            SUPPL
          3. Appl No
            217729
            Application Docs Date
            2026-03-06 00:00:00
            Application Docs ID
            85288
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            2
            Submission Type
            SUPPL
          all submission records
          1. Appl No
            217729
            Review Priority
            PRIORITY
            Submission Class Code ID
            12
            Submission No
            1
            Submission Status
            AP
            Submission Status Date
            2023-09-26 00:00:00
            Submission Type
            ORIG
            Submissions Public Notes
          2. Appl No
            217729
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            1
            Submission Status
            AP
            Submission Status Date
            2024-12-03 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          3. Appl No
            217729
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            2
            Submission Status
            AP
            Submission Status Date
            2026-03-02 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          application number
          NDA217729
          approval interpretation
          Application linkage and approved submission are not indication-level current approval verification
          current indication status
          not_reconciled
          has approved submission record
          true
          latest approved submission date
          2026-03-02
          latest label selection rule
          max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
          latest posted label documents
          1. Appl No
            217729
            Application Docs Date
            2026-03-06 00:00:00
            Application Docs ID
            85288
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            2
            Submission Type
            SUPPL
          official application record
          Appl No
          217729
          Appl Public Notes
          Appl Type
          NDA
          Sponsor Name
          PF PRISM CV
          openfda application present
          true
          products
          1. Active Ingredient
            BOSUTINIB MONOHYDRATE
            Appl No
            217729
            Drug Name
            BOSULIF
            Form
            CAPSULE;ORAL
            Product No
            001
            Reference Drug
            1
            Reference Standard
            0
            Strength
            EQ 50MG BASE
            marketing status
            1. Prescription
          2. Active Ingredient
            BOSUTINIB MONOHYDRATE
            Appl No
            217729
            Drug Name
            BOSULIF
            Form
            CAPSULE;ORAL
            Product No
            002
            Reference Drug
            1
            Reference Standard
            1
            Strength
            EQ 100MG BASE
            marketing status
            1. Prescription

        Source passages and status connections

        Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

        Passage 1 · positive indication candidate
        application numbers
        1. NDA203341
        2. NDA217729
        brand names
        1. BOSULIF
        classification reasons
        1. explicit_positive_indication_predicate
        2. no_tumor_directed_keyword_in_positive_statement
        clinical review status
        pending
        content role
        positive_indication_candidate
        context span
        end
        266
        end exclusive
        true
        exact text
        1 INDICATIONS AND USAGE BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to p
        label id
        ca8600d9-46e6-402d-89f9-bc6a156bf751
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
        start
        0
        current approval status
        not_reconciled
        duplicate text group
        dup-b6344c6b4fceae54e781
        extraction review status
        automated_candidate_pending_source_review
        generic names
        1. BOSUTINIB
        id
        ind-span-f931333f610e39a88265
        label id
        ca8600d9-46e6-402d-89f9-bc6a156bf751
        positive predicate support span
        end
        44
        end exclusive
        true
        exact text
        is indicated
        label id
        ca8600d9-46e6-402d-89f9-bc6a156bf751
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
        start
        32
        qualifier mentions
          regulatory links
            schema version
            0.1.0
            source batch sha256
            a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
            source defined aliases
              source span
              end
              66
              end exclusive
              true
              exact text
              1 INDICATIONS AND USAGE BOSULIF is indicated for the treatment of:
              label id
              ca8600d9-46e6-402d-89f9-bc6a156bf751
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
              start
              0
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%22ca8600d9-46e6-402d-89f9-bc6a156bf751%22
              spl effective date
              2026-03-10
              spl set id
              adc84ad5-a04d-4fee-9ba8-91f7abd928e3
              spl version
              32
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              non_oncology_or_unclear_candidate
              Passage 2 · positive indication candidate
              application numbers
              1. NDA203341
              2. NDA217729
              brand names
              1. BOSULIF
              classification reasons
              1. inherited_predicate_from_same_label_section_requires_review
              2. tumor_or_malignant_hematology_words_in_positive_statement
              clinical review status
              pending
              content role
              positive_indication_candidate
              context span
              end
              526
              end exclusive
              true
              exact text
              1 INDICATIONS AND USAGE BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for
              label id
              ca8600d9-46e6-402d-89f9-bc6a156bf751
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
              start
              0
              current approval status
              not_reconciled
              duplicate text group
              dup-2f1af7a1b7945fdad40b
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. BOSUTINIB
              id
              ind-span-632b1178cea8c2b9088e
              label id
              ca8600d9-46e6-402d-89f9-bc6a156bf751
              positive predicate support span
              end
              44
              end exclusive
              true
              exact text
              is indicated
              label id
              ca8600d9-46e6-402d-89f9-bc6a156bf751
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
              start
              32
              qualifier mentions
              1. context exact
                • Adult and pediatric patients 1 year of age and older with chronic
                kind
                age
                polarity
                not_inferred
                span
                end
                74
                end exclusive
                true
                exact text
                Adult
                label id
                ca8600d9-46e6-402d-89f9-bc6a156bf751
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                start
                69
              2. context exact
                • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphi
                kind
                age
                polarity
                not_inferred
                span
                end
                97
                end exclusive
                true
                exact text
                pediatric patients
                label id
                ca8600d9-46e6-402d-89f9-bc6a156bf751
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                start
                79
              regulatory links
                schema version
                0.1.0
                source batch sha256
                a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
                source defined aliases
                  source span
                  end
                  326
                  end exclusive
                  true
                  exact text
                  • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] .
                  label id
                  ca8600d9-46e6-402d-89f9-bc6a156bf751
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                  start
                  67
                  source url
                  https://api.fda.gov/drug/label.json?search=id%3A%22ca8600d9-46e6-402d-89f9-bc6a156bf751%22
                  spl effective date
                  2026-03-10
                  spl set id
                  adc84ad5-a04d-4fee-9ba8-91f7abd928e3
                  spl version
                  32
                  structured fields status
                  not_extracted_no_values_inferred_from_mentions
                  structured indication
                  age
                  Source null
                  approval pathway
                  Source null
                  biomarker and test
                  Source null
                  disease stage
                  Source null
                  limitations
                  Source null
                  line
                  Source null
                  prior therapy
                  Source null
                  regimen
                  Source null
                  tumor histology
                  Source null
                  use intent
                  tumor_directed_candidate
                  Passage 3 · positive indication candidate
                  application numbers
                  1. NDA203341
                  2. NDA217729
                  brand names
                  1. BOSULIF
                  classification reasons
                  1. inherited_predicate_from_same_label_section_requires_review
                  2. tumor_or_malignant_hematology_words_in_positive_statement
                  clinical review status
                  pending
                  content role
                  positive_indication_candidate
                  context span
                  end
                  681
                  end exclusive
                  true
                  exact text
                  chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resis
                  label id
                  ca8600d9-46e6-402d-89f9-bc6a156bf751
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                  start
                  127
                  current approval status
                  not_reconciled
                  duplicate text group
                  dup-282d4e698a94d9b5103f
                  extraction review status
                  automated_candidate_pending_source_review
                  generic names
                  1. BOSUTINIB
                  id
                  ind-span-3da9851b4315d0379d54
                  label id
                  ca8600d9-46e6-402d-89f9-bc6a156bf751
                  positive predicate support span
                  end
                  44
                  end exclusive
                  true
                  exact text
                  is indicated
                  label id
                  ca8600d9-46e6-402d-89f9-bc6a156bf751
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                  start
                  32
                  qualifier mentions
                  1. context exact
                    • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML wi
                    kind
                    age
                    polarity
                    not_inferred
                    span
                    end
                    343
                    end exclusive
                    true
                    exact text
                    Adult patients
                    label id
                    ca8600d9-46e6-402d-89f9-bc6a156bf751
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                    start
                    329
                  regulatory links
                    schema version
                    0.1.0
                    source batch sha256
                    a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
                    source defined aliases
                      source span
                      end
                      481
                      end exclusive
                      true
                      exact text
                      • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] .
                      label id
                      ca8600d9-46e6-402d-89f9-bc6a156bf751
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                      start
                      327
                      source url
                      https://api.fda.gov/drug/label.json?search=id%3A%22ca8600d9-46e6-402d-89f9-bc6a156bf751%22
                      spl effective date
                      2026-03-10
                      spl set id
                      adc84ad5-a04d-4fee-9ba8-91f7abd928e3
                      spl version
                      32
                      structured fields status
                      not_extracted_no_values_inferred_from_mentions
                      structured indication
                      age
                      Source null
                      approval pathway
                      Source null
                      biomarker and test
                      Source null
                      disease stage
                      Source null
                      limitations
                      Source null
                      line
                      Source null
                      prior therapy
                      Source null
                      regimen
                      Source null
                      tumor histology
                      Source null
                      use intent
                      tumor_directed_candidate
                      Passage 4 · positive indication candidate
                      application numbers
                      1. NDA203341
                      2. NDA217729
                      brand names
                      1. BOSULIF
                      classification reasons
                      1. explicit_positive_indication_predicate
                      2. no_tumor_directed_keyword_in_positive_statement
                      clinical review status
                      pending
                      content role
                      positive_indication_candidate
                      context span
                      end
                      742
                      end exclusive
                      true
                      exact text
                      e Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients w
                      label id
                      ca8600d9-46e6-402d-89f9-bc6a156bf751
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                      start
                      282
                      current approval status
                      not_reconciled
                      duplicate text group
                      dup-e6735fe2ffeb6cfe8b37
                      extraction review status
                      automated_candidate_pending_source_review
                      generic names
                      1. BOSUTINIB
                      id
                      ind-span-36ea8ef363a6e1f6a1c1
                      label id
                      ca8600d9-46e6-402d-89f9-bc6a156bf751
                      positive predicate support span
                      end
                      521
                      end exclusive
                      true
                      exact text
                      is a kinase inhibitor indicated
                      label id
                      ca8600d9-46e6-402d-89f9-bc6a156bf751
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                      start
                      490
                      qualifier mentions
                        regulatory links
                          schema version
                          0.1.0
                          source batch sha256
                          a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
                          source defined aliases
                            source span
                            end
                            542
                            end exclusive
                            true
                            exact text
                            BOSULIF is a kinase inhibitor indicated for the treatment of
                            label id
                            ca8600d9-46e6-402d-89f9-bc6a156bf751
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                            start
                            482
                            source url
                            https://api.fda.gov/drug/label.json?search=id%3A%22ca8600d9-46e6-402d-89f9-bc6a156bf751%22
                            spl effective date
                            2026-03-10
                            spl set id
                            adc84ad5-a04d-4fee-9ba8-91f7abd928e3
                            spl version
                            32
                            structured fields status
                            not_extracted_no_values_inferred_from_mentions
                            structured indication
                            age
                            Source null
                            approval pathway
                            Source null
                            biomarker and test
                            Source null
                            disease stage
                            Source null
                            limitations
                            Source null
                            line
                            Source null
                            prior therapy
                            Source null
                            regimen
                            Source null
                            tumor histology
                            Source null
                            use intent
                            non_oncology_or_unclear_candidate
                            Passage 5 · positive indication candidate
                            application numbers
                            1. NDA203341
                            2. NDA217729
                            brand names
                            1. BOSULIF
                            classification reasons
                            1. inherited_predicate_from_same_label_section_requires_review
                            2. tumor_or_malignant_hematology_words_in_positive_statement
                            clinical review status
                            pending
                            content role
                            positive_indication_candidate
                            context span
                            end
                            836
                            end exclusive
                            true
                            exact text
                            with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )
                            label id
                            ca8600d9-46e6-402d-89f9-bc6a156bf751
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                            start
                            343
                            current approval status
                            not_reconciled
                            duplicate text group
                            dup-85ce97d28531275f900a
                            extraction review status
                            automated_candidate_pending_source_review
                            generic names
                            1. BOSUTINIB
                            id
                            ind-span-554a76cfec1ad0b6f13a
                            label id
                            ca8600d9-46e6-402d-89f9-bc6a156bf751
                            positive predicate support span
                            end
                            44
                            end exclusive
                            true
                            exact text
                            is indicated
                            label id
                            ca8600d9-46e6-402d-89f9-bc6a156bf751
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                            start
                            32
                            qualifier mentions
                            1. context exact
                              • adult and pediatric patients 1 year of age and older with chronic
                              kind
                              age
                              polarity
                              not_inferred
                              span
                              end
                              550
                              end exclusive
                              true
                              exact text
                              adult
                              label id
                              ca8600d9-46e6-402d-89f9-bc6a156bf751
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                              start
                              545
                            2. context exact
                              • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myel
                              kind
                              age
                              polarity
                              not_inferred
                              span
                              end
                              573
                              end exclusive
                              true
                              exact text
                              pediatric patients
                              label id
                              ca8600d9-46e6-402d-89f9-bc6a156bf751
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                              start
                              555
                            regulatory links
                              schema version
                              0.1.0
                              source batch sha256
                              a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
                              source defined aliases
                                source span
                                end
                                717
                                end exclusive
                                true
                                exact text
                                • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.
                                label id
                                ca8600d9-46e6-402d-89f9-bc6a156bf751
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                                start
                                543
                                source url
                                https://api.fda.gov/drug/label.json?search=id%3A%22ca8600d9-46e6-402d-89f9-bc6a156bf751%22
                                spl effective date
                                2026-03-10
                                spl set id
                                adc84ad5-a04d-4fee-9ba8-91f7abd928e3
                                spl version
                                32
                                structured fields status
                                not_extracted_no_values_inferred_from_mentions
                                structured indication
                                age
                                Source null
                                approval pathway
                                Source null
                                biomarker and test
                                Source null
                                disease stage
                                Source null
                                limitations
                                Source null
                                line
                                Source null
                                prior therapy
                                Source null
                                regimen
                                Source null
                                tumor histology
                                Source null
                                use intent
                                tumor_directed_candidate
                                Passage 6 · unclassified context
                                application numbers
                                1. NDA203341
                                2. NDA217729
                                brand names
                                1. BOSULIF
                                classification reasons
                                1. no_unambiguous_positive_indication_predicate
                                clinical review status
                                pending
                                content role
                                unclassified_context
                                context span
                                end
                                836
                                end exclusive
                                true
                                exact text
                                ted for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )
                                label id
                                ca8600d9-46e6-402d-89f9-bc6a156bf751
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                                start
                                518
                                current approval status
                                not_reconciled
                                duplicate text group
                                dup-de52e1e59a9d38bc2a47
                                extraction review status
                                automated_candidate_pending_source_review
                                generic names
                                1. BOSUTINIB
                                id
                                ind-span-f448ca81006698688081
                                label id
                                ca8600d9-46e6-402d-89f9-bc6a156bf751
                                positive predicate support span
                                Source null
                                qualifier mentions
                                  regulatory links
                                    schema version
                                    0.1.0
                                    source batch sha256
                                    a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
                                    source defined aliases
                                      source span
                                      end
                                      723
                                      end exclusive
                                      true
                                      exact text
                                      ( 1 )
                                      label id
                                      ca8600d9-46e6-402d-89f9-bc6a156bf751
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                                      start
                                      718
                                      source url
                                      https://api.fda.gov/drug/label.json?search=id%3A%22ca8600d9-46e6-402d-89f9-bc6a156bf751%22
                                      spl effective date
                                      2026-03-10
                                      spl set id
                                      adc84ad5-a04d-4fee-9ba8-91f7abd928e3
                                      spl version
                                      32
                                      structured fields status
                                      not_extracted_no_values_inferred_from_mentions
                                      structured indication
                                      age
                                      Source null
                                      approval pathway
                                      Source null
                                      biomarker and test
                                      Source null
                                      disease stage
                                      Source null
                                      limitations
                                      Source null
                                      line
                                      Source null
                                      prior therapy
                                      Source null
                                      regimen
                                      Source null
                                      tumor histology
                                      Source null
                                      use intent
                                      unclear
                                      Passage 7 · unclassified context
                                      application numbers
                                      1. NDA203341
                                      2. NDA217729
                                      brand names
                                      1. BOSULIF
                                      classification reasons
                                      1. no_unambiguous_positive_indication_predicate
                                      clinical review status
                                      pending
                                      content role
                                      unclassified_context
                                      context span
                                      end
                                      836
                                      end exclusive
                                      true
                                      exact text
                                      r the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )
                                      label id
                                      ca8600d9-46e6-402d-89f9-bc6a156bf751
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                                      start
                                      524
                                      current approval status
                                      not_reconciled
                                      duplicate text group
                                      dup-c4012b9b9d768eb6fa87
                                      extraction review status
                                      automated_candidate_pending_source_review
                                      generic names
                                      1. BOSUTINIB
                                      id
                                      ind-span-a9eff7baca8e6b825fbc
                                      label id
                                      ca8600d9-46e6-402d-89f9-bc6a156bf751
                                      positive predicate support span
                                      Source null
                                      qualifier mentions
                                      1. context exact
                                        • adult patients with accelerated, or blast phase Ph+ CML with resistance or
                                        kind
                                        age
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        740
                                        end exclusive
                                        true
                                        exact text
                                        adult patients
                                        label id
                                        ca8600d9-46e6-402d-89f9-bc6a156bf751
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                                        start
                                        726
                                      regulatory links
                                        schema version
                                        0.1.0
                                        source batch sha256
                                        a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
                                        source defined aliases
                                          source span
                                          end
                                          830
                                          end exclusive
                                          true
                                          exact text
                                          • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
                                          label id
                                          ca8600d9-46e6-402d-89f9-bc6a156bf751
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                                          start
                                          724
                                          source url
                                          https://api.fda.gov/drug/label.json?search=id%3A%22ca8600d9-46e6-402d-89f9-bc6a156bf751%22
                                          spl effective date
                                          2026-03-10
                                          spl set id
                                          adc84ad5-a04d-4fee-9ba8-91f7abd928e3
                                          spl version
                                          32
                                          structured fields status
                                          not_extracted_no_values_inferred_from_mentions
                                          structured indication
                                          age
                                          Source null
                                          approval pathway
                                          Source null
                                          biomarker and test
                                          Source null
                                          disease stage
                                          Source null
                                          limitations
                                          Source null
                                          line
                                          Source null
                                          prior therapy
                                          Source null
                                          regimen
                                          Source null
                                          tumor histology
                                          Source null
                                          use intent
                                          unclear
                                          Passage 8 · unclassified context
                                          application numbers
                                          1. NDA203341
                                          2. NDA217729
                                          brand names
                                          1. BOSULIF
                                          classification reasons
                                          1. no_unambiguous_positive_indication_predicate
                                          clinical review status
                                          pending
                                          content role
                                          unclassified_context
                                          context span
                                          end
                                          836
                                          end exclusive
                                          true
                                          exact text
                                          elogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )
                                          label id
                                          ca8600d9-46e6-402d-89f9-bc6a156bf751
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                                          start
                                          631
                                          current approval status
                                          not_reconciled
                                          duplicate text group
                                          dup-de52e1e59a9d38bc2a47
                                          extraction review status
                                          automated_candidate_pending_source_review
                                          generic names
                                          1. BOSUTINIB
                                          id
                                          ind-span-267cfaca002a00f0d391
                                          label id
                                          ca8600d9-46e6-402d-89f9-bc6a156bf751
                                          positive predicate support span
                                          Source null
                                          qualifier mentions
                                            regulatory links
                                              schema version
                                              0.1.0
                                              source batch sha256
                                              a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
                                              source defined aliases
                                                source span
                                                end
                                                836
                                                end exclusive
                                                true
                                                exact text
                                                ( 1 )
                                                label id
                                                ca8600d9-46e6-402d-89f9-bc6a156bf751
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                2d81d5225d3a5876c721c28eb5c5c170e3bc38409b95069bb900f1b2e7f61a8b
                                                start
                                                831
                                                source url
                                                https://api.fda.gov/drug/label.json?search=id%3A%22ca8600d9-46e6-402d-89f9-bc6a156bf751%22
                                                spl effective date
                                                2026-03-10
                                                spl set id
                                                adc84ad5-a04d-4fee-9ba8-91f7abd928e3
                                                spl version
                                                32
                                                structured fields status
                                                not_extracted_no_values_inferred_from_mentions
                                                structured indication
                                                age
                                                Source null
                                                approval pathway
                                                Source null
                                                biomarker and test
                                                Source null
                                                disease stage
                                                Source null
                                                limitations
                                                Source null
                                                line
                                                Source null
                                                prior therapy
                                                Source null
                                                regimen
                                                Source null
                                                tumor histology
                                                Source null
                                                use intent
                                                unclear

                                                Preserved source evidence · Not medical advice